淋巴瘤诊断中成纤维细胞激活蛋白与糖酵解的比较:68Ga-FAPI PET/CT与18F-FDG PET/CT的对比研究
该前瞻性研究纳入186例不同亚型淋巴瘤患者,同期行68Ga-FAPI与18F-FDG PET/CT,并用免疫组化评估FAP、己糖激酶2和葡萄糖转运蛋白1表达。18F-FDG PET/CT分期准确率更高(98.4% vs 86.0%),且检出更多淋巴结和结外病灶;68Ga-FAPI PET/CT在FAP低表达淋巴瘤中诊断效能劣于18F-FDG PET/CT,但可能作为后者的补充。
要点
- 18F-FDG PET/CT分期准确率98.4%,高于68Ga-FAPI PET/CT的86.0%。
- 18F-FDG PET/CT检出淋巴结病灶4,624个、结外病灶1,304个,均多于68Ga-FAPI PET/CT的2,196个和845个。
- FAP仅在基质细胞表达,GLUT1和己糖激酶2在淋巴瘤细胞和肿瘤微环境均过表达。
核心结论
- 68Ga-FAPI PET/CT在FAP低表达淋巴瘤中的诊断效能劣于18F-FDG PET/CT,但前者可能补充后者并有助于揭示淋巴瘤的分子特征。
研究设计与样本
- 前瞻性研究,自2020年5月至2021年12月招募不同淋巴瘤亚型参与者,均行68Ga-FAPI和18F-FDG PET/CT,并行免疫组化评估FAP、己糖激酶2和GLUT1表达。
- 共纳入186例参与者(中位年龄52岁,四分位间距41-64岁;女性95例)。
- 采用配对样本t检验和Wilcoxon符号秩检验比较参数,用Spearman秩相关系数分析免疫组化结果与示踪剂摄取的相关性。
主要发现
- 双示踪剂显像产生3种显像模式。
- 18F-FDG PET/CT在5,980个淋巴瘤病灶中检出淋巴结病灶4,624个 vs 68Ga-FAPI PET/CT检出2,196个,检出结外病灶1,304个 vs 845个。
- 观察到52个68Ga-FAPI阳性/18F-FDG阴性病灶和2,939个68Ga-FAPI阴性/18F-FDG阳性病灶。
- 在许多淋巴瘤亚型中,半定量评估显示68Ga-FAPI与18F-FDG PET/CT的SUVmax或靶/肝比值无显著差异(P > 0.05)。
- GLUT1和己糖激酶2在淋巴瘤细胞和肿瘤微环境中均过表达,而FAP仅在基质细胞中表达;FAP表达与68Ga-FAPI SUVmax正相关(r = 0.622,P = 0.001),GLUT1表达与18F-FDG SUVmax正相关(r = 0.835,P < 0.001)。
关键数值与推荐
- 18F-FDG PET/CT分期准确率为98.4%,68Ga-FAPI PET/CT为86.0%。
- 在5,980个淋巴瘤病灶中,18F-FDG PET/CT检出淋巴结病灶4,624个 vs 68Ga-FAPI PET/CT 2,196个,检出结外病灶1,304个 vs 845个。
- 52个病灶为68Ga-FAPI阳性/18F-FDG阴性,2,939个病灶为68Ga-FAPI阴性/18F-FDG阳性。
- FAP表达与68Ga-FAPI SUVmax正相关(r = 0.622,P = 0.001),GLUT1表达与18F-FDG SUVmax正相关(r = 0.835,P < 0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Our objective was to compare the diagnostic performance of 68Ga-labeled fibroblast activation protein (FAP) inhibitor (FAPI) and 18F-labeled FDG PET/CT in diagnosing lymphomas and to characterize the influence of FAP and glycolytic markers on tracer uptake by involved lesions. Methods: Participants with different lymphoma subtypes who were prospectively recruited from May 2020 to December 2021 underwent 68Ga-FAPI and 18F-FDG PET/CT. Immunohistochemistry was performed to evaluate FAP, hexokinase 2, and glucose transporter 1 (GLUT1) expression, and the paired-samples t test and Wilcoxon signed-rank test were used to compare parameters. The correlation between the immunochemistry results and tracer uptake was determined by the Spearman rank correlation coefficient. Results: In total, 186 participants (median age, 52 y [interquartile range, 41-64 y]; 95 women) were included. Dual-tracer imaging produced 3 types of imaging profiles. 18F-FDG PET possessed a higher staging accuracy (98.4%) than 68Ga-FAPI PET (86.0%). In 5,980 lymphoma lesions, 18F-FDG PET/CT detected more nodal (4,624 vs. 2,196) and extranodal (1,304 vs. 845) lesions than 68Ga-FAPI PET/CT. Additionally, 52 68Ga-FAPI-positive/18F-FDG-negative lesions and 2,939 68Ga-FAPI-negative/18F-FDG-positive lesions were observed. In many lymphoma subtypes, semiquantitative evaluation revealed no significant differences in SUVmax or target-to-liver ratios between 68Ga-FAPI and 18F-FDG PET/CT (P > 0.05). Interestingly, GLUT1 and hexokinase 2 were overexpressed both in lymphoma cells and in the tumor microenvironment, whereas FAP was expressed only in stromal cells. FAP and GLUT1 expression correlated positively with 68Ga-FAPI SUVmax (r = 0.622, P = 0.001) and 18F-FDG SUVmax (r = 0.835, P < 0.001), respectively. Conclusion: 68Ga-FAPI PET/CT was inferior to 18F-FDG PET/CT in diagnosing lymphomas with low FAP expression. However, the former may supplement the latter and help reveal the molecular profile of lymphomas.
引用
- Chen X, Wang S, Lai Y, et al. Fibroblast Activation Protein and Glycolysis in Lymphoma Diagnosis: Comparison of 68Ga-FAPI PET/CT and 18F-FDG PET/CT. J Nucl Med. 2023. PMID: 37385675. doi:10.2967/jnumed.123.265530
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。